Remacemide

DB06458ExperimentalSmall molecule

Investigated for use/treatment in epilepsy, huntington's disease, and parkinson's disease.

Mechanism: Pharmacologically active on NMDA receptor and Voltage-gated sodium channel alpha subunit
Curator reviewed
Primary indication: Investigated for use/treatment in epilepsy, huntington's disease, and parkinson's disease.Curator reviewed
Formula / weight: C₁₇H₂₀N₂O · 268.36 g/mol (avg)
Code names: AR-R-12924 · FPL-12924 · PR-934-423 · PR-934423A

Resolves to

Compound

Structure

InChIKeyYSGASDXSLKIKOD-UHFFFAOYSA-NSMILESCC(CC1=CC=CC=C1)(NC(=O)CN)C1=CC=CC=C1

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

944Drug interactionsStructured to mechanism, not free text

8+ReferencesStructured and connected to the statements they support

Which companies are running trials of Remacemide, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.